Urologix' Building Momentum, New COO Help Boost Stock 63% In November
This article was originally published in The Gray Sheet
Executive Summary
Continued momentum in sales of Urologix' Targis microwave catheter-based system for treatment of benign prostatic hyperplasia and procedure kit revenues, as well as growing acceptance of a "per-procedure" marketing strategy and strong additions to top management, helped Urologix stock jump 62.7% in November. The issue gained 2 points to close at 5-3/16
You may also be interested in...
Kimberly-Clark Enters $3 Bil. Glove Market Via $850 Mil. Safeskin Buy
Acquisition of disposable medical glove maker Safeskin marks Kimberly-Clark's entrance into the $3 bil. worldwide latex and synthetic glove market and will boost sales of the firm's professional health care segment to approximately $950 mil. in 2000.
EU: Good News For IVDs And For Future Transparency Of Medtech Compliance
The IVD industry has long been awaiting a further extension of the deadlines for compliance with the IVD Regulation and for the launch date of the Eudamed database to be brought forward.
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.